Clavulanate lithium is primarily used in combination with beta-lactam antibiotics, such as amoxicillin, to enhance their effectiveness against bacteria that produce beta-lactamase enzymes. These enzymes can render certain antibiotics ineffective by breaking them down. By inhibiting beta-lactamase, clavulanate lithium allows the antibiotic to remain active, thereby improving its ability to treat infections. This combination is commonly prescribed for respiratory tract infections, urinary tract infections, skin and soft tissue infections, and other bacterial infections where resistance due to beta-lactamase production is a concern. Its role is crucial in combating antibiotic resistance and ensuring the efficacy of treatment in clinical settings.